{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:40:12Z","timestamp":1780537212713,"version":"3.54.1"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non\u2013small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.<\/jats:p>","DOI":"10.1093\/ckj\/sfac062","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T20:14:27Z","timestamp":1645733667000},"page":"1475-1482","source":"Crossref","is-referenced-by-count":21,"title":["Anaplastic lymphoma kinase inhibitors and their effect on the kidney"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-9730","authenticated-orcid":false,"given":"Marco","family":"Bonilla","sequence":"first","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra Northwell , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra Northwell , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-9837","authenticated-orcid":false,"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peupliers Private Hospital , Ramsay G\u00e9n\u00e9rale de Sant\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"2022072308582232900_bib1","volume-title":"Cancer Facts & Figures 2015","author":"American Cancer Society","year":"2015"},{"key":"2022072308582232900_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2022072308582232900_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"2022072308582232900_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"2022072308582232900_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/PO.21.00078","article-title":"ALK-directed therapy in non-NSCLC malignancies: are we ready?","author":"Salgia","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2022072308582232900_bib6","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"2022072308582232900_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"key":"2022072308582232900_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/apm.12940","article-title":"Targeting anaplastic lymphoma kinase in neuroblastoma","volume":"127","author":"Umapathy","year":"2019","journal-title":"APMIS"},{"key":"2022072308582232900_bib9","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-21-0627","article-title":"ALK inhibitors in neuroblastoma: a sprint from bench to bedside","volume":"27","author":"Schulte","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2022072308582232900_bib10","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/14656566.2021.1953470","article-title":"Advances in pharmacotherapy for neuroblastoma","volume":"22","author":"Pezeshki","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2022072308582232900_bib11","doi-asserted-by":"crossref","first-page":"e28185","DOI":"10.1002\/pbc.28185","article-title":"The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript","volume":"67","author":"Brunac","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2022072308582232900_bib12","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2147\/DDDT.S147384","article-title":"Entrectinib and other ALK\/TRK inhibitors for the treatment of neuroblastoma","volume":"12","author":"Pacenta","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2022072308582232900_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","article-title":"New treatment strategies for metastatic pancreatic ductal adenocarcinoma","volume":"80","author":"Singh","year":"2020","journal-title":"Drugs"},{"key":"2022072308582232900_bib14","doi-asserted-by":"crossref","first-page":"724815","DOI":"10.3389\/fonc.2021.724815","article-title":"ALK rearrangement-positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: a case report","volume":"11","author":"Ou","year":"2021","journal-title":"Front Oncol"},{"key":"2022072308582232900_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1634\/theoncologist.2018-0439","article-title":"Carcinoma of unknown primary with EML4-ALK fusion response to ALK inhibitors","volume":"24","author":"Zhao","year":"2019","journal-title":"Oncologist"},{"key":"2022072308582232900_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000511069","article-title":"Colorectal cancer with EML4-ALK fusion gene response to alectinib: a case report and review of the literature","volume":"14","author":"Hsiao","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2022072308582232900_bib17","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/bjc.2015.401","article-title":"Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer","volume":"113","author":"Amatu","year":"2015","journal-title":"Br J Cancer"},{"key":"2022072308582232900_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2022072308582232900_bib19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/ph14111126","article-title":"Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells","volume":"14","author":"Boulos","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2022072308582232900_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-018-0169-1","article-title":"The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia","volume":"9","author":"Moharram","year":"2019","journal-title":"Blood Cancer J"},{"key":"2022072308582232900_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","article-title":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","volume":"6","author":"Sch\u00f6ffski","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022072308582232900_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"2022072308582232900_bib23","first-page":"PO.20.00534","article-title":"Clinical responses to crizotinib, alectinib, and lorlatinib in a metastatic colorectal carcinoma patient with ALK gene rearrangement: a case report","volume":"5","author":"He","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2022072308582232900_bib24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/PO.20.00383","article-title":"Impact of ALK inhibitors in patients with ALK-rearranged nonlung solid tumors","author":"Takeyasu","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2022072308582232900_bib25","doi-asserted-by":"crossref","first-page":"TPS3154","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3154","article-title":"Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): a novel platform umbrella trial","volume":"39","author":"Drilon","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib26","doi-asserted-by":"crossref","first-page":"TPS3155","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3155","article-title":"Alpha-T: an innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting","volume":"39","author":"Kurzrock","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri","year":"2016","journal-title":"Kidney Int Rep"},{"key":"2022072308582232900_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","article-title":"Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review","volume":"134","author":"Kassem","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022072308582232900_bib29","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"key":"2022072308582232900_bib30","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"2022072308582232900_bib31","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"2022072308582232900_bib32","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"2022072308582232900_bib33","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/JTO.0b013e3182570919","article-title":"Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer","volume":"7","author":"Yasuda","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2022072308582232900_bib34","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"2022072308582232900_bib35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022072308582232900_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"2022072308582232900_bib37","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","article-title":"Synthesis, structure activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials","volume":"56","author":"Marsilje","year":"2013","journal-title":"J Med Chem"},{"key":"2022072308582232900_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14728222.2014.936383","article-title":"Looking for a new panacea in ALK rearranged NSCLC: may be ceritinib?","volume":"18","author":"Rolfo","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"2022072308582232900_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2014-0143","article-title":"Approval after phase I: ceritinib runs the three-minute mile","volume":"19","author":"Chabner","year":"2014","journal-title":"Oncologist"},{"key":"2022072308582232900_bib40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced nonsmall-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1\u20132 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"2022072308582232900_bib41","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1200\/jco.2013.31.15_suppl.8031","article-title":"First-in-human dose-finding study of the ALK\/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results","volume":"31","author":"Camidge","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib42","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1538-7445.AM2015-2827","article-title":"Abstract 2827: discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants","volume":"75","author":"Huang","year":"2015","journal-title":"Cancer Res"},{"key":"2022072308582232900_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1538-7445.AM2015-781","article-title":"Abstract 781: the potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models","volume":"75","author":"Zhang","year":"2015","journal-title":"Cancer Res"},{"key":"2022072308582232900_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"2022072308582232900_bib45","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1158\/0008-5472.CAN-14-3817","article-title":"Tackling crizotinib resistance: the pathway from drug discovery to the pediatric clinic","volume":"75","author":"Tucker","year":"2015","journal-title":"Cancer Res"},{"key":"2022072308582232900_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/2159-8290.CD-15-1056","article-title":"The ALK\/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma","volume":"6","author":"Infarinato","year":"2016","journal-title":"Cancer Discov"},{"key":"2022072308582232900_bib47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1538-7445.AM2015-764","article-title":"Abstract 764: rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models","volume":"75","author":"Wei","year":"2015","journal-title":"Cancer Res"},{"key":"2022072308582232900_bib48","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.21037\/cco.2018.10.12","article-title":"Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC","volume":"8","author":"Li","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"2022072308582232900_bib49","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/fon-2017-0619","article-title":"Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer","volume":"14","author":"Singhi","year":"2018","journal-title":"Future Oncol"},{"key":"2022072308582232900_bib50","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2022072308582232900_bib51","doi-asserted-by":"crossref","first-page":"abstract 2517","DOI":"10.1200\/jco.2015.33.15_suppl.2517","article-title":"Alka-372-001: First-in-human, phase I study of entrectinib\u2014an oral pantrk, ROS1, and ALK inhibitor\u2014in patients with advanced solid tumors with relevant molecular alterations","volume":"33","author":"De Braud","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib52","doi-asserted-by":"crossref","first-page":"abstract 2596","DOI":"10.1200\/jco.2015.33.15_suppl.2596","article-title":"STARTRK-1: Phase 1\/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations","volume":"33","author":"Patel","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"2022072308582232900_bib54","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-Positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2022072308582232900_bib55","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022072308582232900_bib56","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2","volume":"34","author":"Crin\u00f2","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022072308582232900_bib57","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/ckj\/sfab078","article-title":"Hypophosphatemia in cancer patients","volume":"14","author":"Adhikari","year":"2021","journal-title":"Clin Kidney J"},{"key":"2022072308582232900_bib58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1078155215592023","article-title":"Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone","volume":"22","author":"Hill","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2022072308582232900_bib59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"key":"2022072308582232900_bib60","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","article-title":"Phase 1\/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non\u2013small cell lung cancer previously treated with crizotinib: results from ASCEND-6","volume":"150","author":"Wu","year":"2020","journal-title":"Lung Cancer"},{"key":"2022072308582232900_bib61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J Med Case Rep"},{"key":"2022072308582232900_bib62","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.2147\/OTT.S136837","article-title":"Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction","volume":"10","author":"Shimada","year":"2017","journal-title":"OncoTargets Ther"},{"key":"2022072308582232900_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5301\/jo-n.5000012","article-title":"Crizotinib: renal safety evaluation","volume":"1","author":"Perazella","year":"2017","journal-title":"J Onco-Nephrol"},{"key":"2022072308582232900_bib64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"2022072308582232900_bib65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00125480-199707000-00032","article-title":"Tacrolimus (FK506)-associated renal pathology","volume":"4","author":"Randhawa","year":"1997","journal-title":"Adv Anat Pathol"},{"key":"2022072308582232900_bib66","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/AAC.10.3.555","article-title":"Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys","volume":"10","author":"Bullock","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"2022072308582232900_bib67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ekir.2020.11.029","article-title":"Acute tubular injury and renal arterial myocyte vacuolization following crizotinib administration","volume":"6","author":"Izzedine","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2022072308582232900_bib68","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/JTO.0000000000000326","article-title":"Development of renal cysts after crizotinib treatment in advanced ALK-positive non\u2013small-cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2022072308582232900_bib69","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med"},{"key":"2022072308582232900_bib70","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.jtho.2018.03.033","article-title":"Minimal change disease induced by lorlatinib","volume":"13","author":"Betton","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2022072308582232900_bib71","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1177\/10781552211004698","article-title":"A possible mechanism of hyperlipidemia in a patient with metastatic non\u2013small cell lung cancer on lorlatinib therapy","volume":"27","author":"McGee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2022072308582232900_bib72","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1078155220961549","article-title":"Lorlatinib induced proteinuria: a case report","volume":"27","author":"Lee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2022072308582232900_bib73","doi-asserted-by":"crossref","first-page":"omy009","DOI":"10.1093\/omcr\/omy009","article-title":"Progressive renal insufficiency related to ALK inhibitor, alectinib","volume":"2018","author":"Nagai","year":"2018","journal-title":"Oxf Med Case Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac062\/43257767\/sfac062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/8\/1475\/45051335\/sfac062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/8\/1475\/45051335\/sfac062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T08:59:10Z","timestamp":1658566750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/8\/1475\/6537423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":73,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,26]]},"published-print":{"date-parts":[[2022,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac062","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,2,26]]}}}